Dexcom Announces Four-for-One Forward Stock Split

Rhea-AI Summary

Dexcom, Inc. (NASDAQ:DXCM) announced a four-for-one forward stock split, pending stockholder approval for an increase in authorized shares from 200 million to 800 million. If approved, each share outstanding on May 19, 2022, will split into four shares. The split-adjusted trading is set to commence on June 10, 2022. This action aims to enhance stock liquidity and accessibility for investors. Further details will be provided in the Preliminary Proxy Statement filed with the U.S. Securities and Exchange Commission on March 25, 2022.

Positive

• Approval of a four-for-one stock split may enhance stock liquidity.
• Increase in authorized shares from 200 million to 800 million allows for future growth.

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom’s common stock.

The Stock Split is contingent upon stockholder approval of a Restated Certificate of Incorporation that would increase the number of authorized shares of common stock from 200,000,000 to 800,000,000.

If stockholders approve the Stock Split, each share of common stock outstanding on May 19, 2022, the date of Dexcom’s 2022 Annual Meeting of Stockholders, will be split into four shares of common stock. Trading is expected to begin on a split-adjusted basis on June 10, 2022.

For additional details, please see Dexcom’s Preliminary Proxy Statement to be filed with the U.S. Securities and Exchange Commission on March 25, 2022.

About DexCom, Inc.

Dexcom empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, and with operations across Europe, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220325005078/en/

Media Contact

James McIntosh

619-884-2118

james.mcintosh@dexcom.com

Investor Contact

Sean Christensen

858-203-6657

sean.christensen@dexcom.com

Source: DexCom, Inc.

FAQ

What is the stock split announced by Dexcom on March 25, 2022?

Dexcom announced a four-for-one forward stock split, pending stockholder approval to increase authorized shares from 200 million to 800 million.

When will Dexcom's stock split take effect?

If approved, trading on a split-adjusted basis will begin on June 10, 2022.

What date will the stockholders vote on Dexcom's stock split?

The stockholders will vote on the stock split on May 19, 2022, during the Annual Meeting.

Where can I find more information about Dexcom's stock split?

Additional details are available in Dexcom's Preliminary Proxy Statement, filed with the U.S. Securities and Exchange Commission on March 25, 2022.